Pfizer Would Explore Where No Other Firm Has Gone Before With Lipitor Switch

The degree of difficulty is tremendous for the first novel switch FDA approves, but it would provide a template others can follow. FDA’s interest in fostering innovative OTC switches could work in favor of proposals to make currently Rx ingredients indicated for a chronic condition available nonprescription.

More from United States

More from North America